Table 1.

Clinical and tumor characteristics according to the lymph node metastasis in patients with ypT0-2

Characteristics	yT0-2N0		yT0-2N+		P
	n	%	n	%
Overall	340		66
Age, years a	59 (49–67)		55 (46–66)		0.072
< 50	89	26%	23	35%	0.347
50–65	150	44%	25	38%
> 65	101	30%	18	27%
Sex					0.951
Female	125	37%	24	36%
Male	215	63%	42	64%
Location					0.460
>10 cm	17	5%	2	3%
6–10 cm	138	41%	25	38%
≤ 5cm	176	52%	35	53%
Unknown	9	3%	4	6%
Clinical stage					0.189
II	144	42%	23	35%
III	173	51%	41	62%
Unknown	23	7%	2	3%
Tumor grade					0.301
G1, G2	295	87%	53	80%
G1, G2	35	10%	9	14%
Unknown	10	3%	4	6%
Examined lymph nodesa	11 (6–15)		11 (7–16)		0.698
Lymphovascular invasionb					<.001
No	256	75%	40	61%
Yes	10	3%	10	15%
Unknown	74	22%	16	24%
Radiation dose, Gyc	50.4 (45–52.5)		40.4 (45–52.5)		0.373
Sphincterpreservation					0.814
No	88	26%	18	27%
Yes	252	74%	48	73%
Adjuvant chemotherapyd	282	83%	60	91%	0.104
Fluoropyrimidine onlye	238	84%	44	73%	0.041
Oxaliplatin-basede	44	16%	16	27%

^aMedian value with interquartile range

^bBased on final resection specimen

^cTumor location was analyzed based on distance (cm) from anal verge

^dPercentage among patients received adjuvant chemotherapy

^eComparison of fluoropyrimidine only versus oxaliplatin-based